Separately, Aegis reaffirmed a positive rating and set a $8.00 target price on shares of Matinas BioPharma Holdings in a research note on Tuesday, March 28th.
Shares of Matinas BioPharma Holdings (MTNB) traded up 4.40% during midday trading on Tuesday, reaching $2.85. 3,374,290 shares of the company’s stock were exchanged. The stock’s market cap is $260.48 million. The stock’s 50 day moving average is $2.71 and its 200-day moving average is $2.53. Matinas BioPharma Holdings has a 12-month low of $0.58 and a 12-month high of $3.99.
Matinas BioPharma Holdings (NASDAQ:MTNB) last released its quarterly earnings results on Tuesday, May 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.21. The company had revenue of $0.02 million for the quarter. On average, equities analysts expect that Matinas BioPharma Holdings will post ($0.28) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/06/16/matinas-biopharma-holdings-inc-mtnb-given-a-6-00-price-target-at-maxim-group-updated-updated-updated.html.
Several hedge funds and other institutional investors have recently made changes to their positions in MTNB. Spark Investment Management LLC purchased a new position in shares of Matinas BioPharma Holdings during the first quarter valued at $105,000. Segantii Capital Management Ltd purchased a new position in shares of Matinas BioPharma Holdings during the first quarter valued at $166,000. KCG Holdings Inc. purchased a new position in shares of Matinas BioPharma Holdings during the first quarter valued at $193,000. Hyman Charles D purchased a new position in shares of Matinas BioPharma Holdings during the first quarter valued at $221,000. Finally, Morgan Stanley purchased a new position in shares of Matinas BioPharma Holdings during the first quarter valued at $300,000.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.